Table 1 Population and baseline characteristics
| Â | Analysed patients | No baseline GFR within the preceding year | ||
|---|---|---|---|---|
Variable | Total population | No AKI in follow-up | AKI in follow-up | Â |
Population | Â | Â | ||
Population in the analysis (%) | 63,722 (100) | 58,904 (92.44) | 4,818 (7.56) | 49,695 |
Average age (years) | 62.67 | 61.79 | 73.42 | 48.93 |
Males (%) | 28,583 (44.86) | 26,097 (44.30) | 2,486 (51.60) | 21,118 (42.50) |
Females (%) | 35,139 (55.14) | 32,807 (55.70) | 2,332 (48.40) | 28,577 (57.50) |
GFR >60Â ml/min/1.73Â m 2 (%) | 50,283 (78.91) | 48,135 (81.72) | 2,148 (44.58) | 47,175 (94.93) |
CKD Stage 3a (%) | 9,702 (15.23) | 8,402 (14.26) | 1,300 (26.98) | 2,060 (4.15) |
CKD Stage 3b (%) | 3,019 (4.74) | 2,038 (3.46) | 981 (20.36) | 399 (0.80) |
CKD Stage 4 (%) | 718 (1.13) | 329 (0.56) | 389 (8.07) | 61 (0.13) |
CKD Total (%) | 13,439 (21.09) | 10,769 (18.28) | 2,670 (55.42) | 2520 (5.07) |
Hypertension (%) | 38,912 (61.07) | 34,962 (59.35) | 3,950 (81.98) | 10,454 (21.03) |
Diabetes (%) | 10,135 (15.91) | 8,815 (14.97) | 1,320 (27.40) | 904 (1.81) |
Ischaemic Heart Disease (%) | 8,033 (12.61) | 6,767 (11.49) | 1,266 (26.28) | 1163 (2.34) |
Heart Failure (%) | 916 (1.48) | 628 (1.07) | 288 (5.98) | 63 (0.13) |
Had an indication for an ACEi/ARB (%) | 26,078 (40.92) | 23,156 (39.31) | 2,922 (60.65) | 6,268 (12.61) |
Were on an ACEi/ARB (%) | 18,698 (71.70) | 16,455 (71.06) | 2,243 (76.76) | 3,035 (6.12) |
Had no indication for an ACEi/ARB (%) | 37,644 (59.08) | 35,748 (60.69) | 1,896 (39.35) | 43,427 (87.39) |
Were on an ACEi/ARB (%) | 5,236 (13.91) | 4,751 (13.29) | 485 (25.58) | 1,095 (2.20) |
On a Thiazide Diuretic (%) | 12,628 (19.82) | 11,384 (19.33) | 1,244 (25.82) | 2,796 (5.63) |
On another Diuretic (%) | 1,724 (2.71) | 1,305 (2.22) | 419 (8.70) | 256 (0.52) |
On a Calcium Channel Blocker (%) | 17,744 (27.85) | 15,785 (26.80) | 1,959 (40.66) | 2,488 (5.01) |
On a Beta Blocker (%) | 3,794 (5.95) | 3,323 (5.64) | 471 (9.78) | 862 (1.73) |
On an Alpha Blocker (%) | 1,004 (1.58) | 849 (1.44) | 155 (3.22) | 58 (0.12) |
On a Centrally Acting Agent (%) | 83 (0.13) | 65 (0.11) | 18 (0.37) | 14 (0.03) |
Proteinuria (at study start): | Â | Â | Â | Â |
None recorded (%) | 35,752 (56.11) | 33,504 (56.88) | 2,248 (46.66) | 35,014 (70.46) |
Normal to Mildly Elevated (%) | 22,552 (35.39) | 20,945 (35.56) | 1,607 (33.35) | 13,342 (26.85) |
Moderately Elevated (%) | 4,473 (7.02) | 3,732 (6.34) | 741 (15.38) | 1,065 (2.14) |
Severely Elevated (%) | 945 (1.48) | 723 (1.23) | 222 (4.61) | 274 (0.55) |